Reuters logo
BRIEF-Avenue Therapeutics sees IPO priced between $5-$7/shr
June 23, 2017 / 10:27 AM / in 4 months

BRIEF-Avenue Therapeutics sees IPO priced between $5-$7/shr

June 23 (Reuters) - Avenue Therapeutics Inc:

* Avenue Therapeutics Inc sees IPO of 5.0 million shares of common stock to be priced between $5 and $7 per share - SEC filing

* Avenue Therapeutics Inc says estimate net proceeds from sale of shares of common stock in IPO will be about $30.0 million

* Avenue Therapeutics Inc plans to use about $16 million of IPO proceeds to fund continued clinical research, development initiatives in connection with IV Tramadol

* Avenue Therapeutics Inc plans to use about $6 million of IPO proceeds to pay off debts to Fortress and NSC Source text: (bit.ly/2tVHOer) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below